A paper outlining the management recommendations for the treatment of renal cell carcinoma has been published.

GlaxoSmithKline (GSK) announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC). These trials were presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The results observed in these trials with pazopanib support further investigations.

Sutent (sunitinib malate) has received a European Association of Urology (EAU) recommendation, as first-line therapy in patients with metastatic renal cell carcinoma of good and intermediate risk, just two months after gaining EU marketing authorization for first line use in all patients with advanced and/or metastatic renal cell carcinoma (mRCC).